Inhaled insulin for type 1 diabetes
Record ID 32006001575
English
Authors' objectives:
Patients with type 1 diabetes require exogenous insulin to control blood glucose levels and to help prevent or reduce the onset of serious diabetic complications. Conventional insulin therapy involves multiple, daily, subcutaneous injections or use of an external insulin pump that delivers insulin via a subcutaneous catheter. Recently, insulin delivery systems that can deliver short-acting insulin via oral inhalation have been developed with the goal of reducing the number of insulin injections required.
Authors' methods:
Review
Details
Project Status:
Completed
Year Published:
2006
URL for published report:
http://www.hayesinc.com/hayes/crd/?crd=4923
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Administration, Inhalation
- Diabetes Mellitus, Type 1
- Hypoglycemic Agents
- Insulin
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
HAYES, Inc.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.